ADRO - Aduro Biotech, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

3.2700

+0.0100 (+0.31%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	3.2600
Open	3.2400
Bid	2.9000 x 800
Ask	3.5100 x 800
Day's Range	3.1200 - 3.3119
52 Week Range	0.9010 - 4.0400
Volume	258,729
Avg. Volume	580,607

Market Cap	264.086M
Beta (5Y Monthly)	0.29
PE Ratio (TTM)	N/A
EPS (TTM)	-0.8280
Earnings Date	May 04, 2020
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	7.00

All

News

Press Releases

Zacks
Aduro Biotech's Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Aduro Biotech.
Zacks
Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?
Aduro Biotech (ADRO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Editas (EDIT) Moves to Buy: Rationale Behind the Upgrade
  Zacks
- HITACHI CHEMICL (HCHMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
  Zacks
Zacks
Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?
Is (ADRO) Outperforming Other Medical Stocks This Year?
GlobeNewswire
Aduro Biotech to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 57th ERA-EDTA Virtual Congress
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host a live conference call and webcast on Monday, June 8, 2020 at 1:00 pm PDT to report data in healthy volunteers from the ongoing Phase 1 study of BION-1301 for the treatment of IgA nephropathy (IgAN) as well as data from long-term nonclinical studies. Members of the Aduro executive team will be joined by Dr. Jonathan Barratt, the Mayer Professor of Renal Medicine at University of Leicester.
Zacks
Is Aduro Biotech (ADRO) Stock a Solid Choice Right Now?
Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Simply Wall St.
New Forecasts: Here's What Analysts Think The Future Holds For Aduro Biotech, Inc. (NASDAQ:ADRO)
Aduro Biotech, Inc. (NASDAQ:ADRO) shareholders will have a reason to smile today, with the analysts making substantial...
Simply Wall St.
Aduro Biotech, Inc. (NASDAQ:ADRO) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
As you might know, Aduro Biotech, Inc. (NASDAQ:ADRO) just kicked off its latest quarterly results with some very...
Zacks
Aduro Biotech (ADRO) Reports Q1 Loss, Tops Revenue Estimates
Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire
Aduro Biotech Provides Business Update and Reports First Quarter 2020 Financial Results
BERKELEY, Calif., May 04, 2020 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
Zacks
Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.
Investors Who Bought Aduro BioTech (NASDAQ:ADRO) Shares Five Years Ago Are Now Down 93%
Aduro BioTech, Inc. (NASDAQ:ADRO) shareholders will doubtless be very grateful to see the share price up 146% in the...
Zacks
Aduro Biotech (ADRO) Down 3.1% Since Last Earnings Report: Can It Rebound?
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Aduro Biotech (ADRO) Gains As Market Dips: What You Should Know
Aduro Biotech (ADRO) closed the most recent trading day at $2.54, moving +1.2% from the previous trading session.
Zacks
Has Aduro Biotech (ADRO) Outpaced Other Medical Stocks This Year?
Is (ADRO) Outperforming Other Medical Stocks This Year?
Zacks
Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.
Zacks
Aduro Biotech (ADRO) Reports Q4 Loss, Lags Revenue Estimates
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -14.29% and -26.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire
Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
BERKELEY, Calif., March 09, 2020 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.
Zacks
Aduro Biotech (ADRO) Stock Moves -0.6%: What You Should Know
Aduro Biotech (ADRO) closed the most recent trading day at $3.33, moving -0.6% from the previous trading session.
Zacks
Is Aduro Biotech (ADRO) Stock Outpacing Its Medical Peers This Year?
Is (ADRO) Outperforming Other Medical Stocks This Year?
GlobeNewswire
Aduro Biotech to Present at the Cowen and Company 40th Annual Health Care Conference
BERKELEY, Calif., Feb. 24, 2020 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is.
Zacks
Aduro Biotech (ADRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Aduro Biotech (ADRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Aduro Biotech (ADRO) Upgraded to Strong Buy: Here's Why
Aduro Biotech (ADRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
GlobeNewswire
Aduro Biotech to Present at the 9th Annual SVB Leerink Global Healthcare Conference
BERKELEY, Calif., Feb. 19, 2020 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is.
GlobeNewswire
Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company earned a $10.0 million development milestone payment under its worldwide licensing agreement with Merck (known as MSD outside the United States and Canada) for the initiation of a Phase 2 clinical trial of MK-5890, an anti-CD27 agonist, in non-small cell lung cancer (NSCLC). “We are thrilled Merck is continuing to advance MK-5890 through development with the initiation of a Phase 2 clinical trial in NSCLC,” said Andrea van Elsas, Ph.D., chief scientific officer of Aduro.
American City Business Journals
East Bay cancer drug developer, jilted by Novartis, to cut 51 jobs
Aduro Biotech Inc. will cut nearly 60% of its workforce and close its European office a month after Swiss partner Novartis AG stepped away from a four-year cancer drug collaboration. The Berkeley company (NASDAQ: ADRO) said the restructuring would cut 51 jobs in all. The cuts are needed to align operating capital and personnel for a collaboration with Eli Lilly and Co. (NYSE: LLY) in cancer, autoimmune diseases and inflammatory diseases, Aduro Chairman, President and CEO Stephen Isaacs said in a statement.